Securities sold along with warrants for 1,750,248 common shares
By Devika Patel
Knoxville, Tenn., April 25 - Radius Health, Inc. settled a $43 million private placement of 8% series B convertible preferred stock on April 23, according to an 8-K filed Thursday with the Securities and Exchange Commission. F2 Bioscience III, LP was among the investors.
The company sold 700,098 preferreds at $61.42 per preferred. Each preferred converts to common stock at $6.142 per share.
Investors also received warrants for 1,750,248 common shares. The warrants are each exercisable at $6.142 until April 23, 2018.
The company may settle additional tranches until May 10.
The private biopharmaceutical company is based in Cambridge, Mass.
| Issuer: | Radius Health, Inc.
|
| Issue: | Series B convertible preferred stock
|
| Amount: | $43,000,019
|
| Preferreds: | 700,098
|
| Price: | $61.42
|
| Dividends: | 8%
|
| Conversion price: | $6.142
|
| Warrants: | For 1,750,248 shares
|
| Warrant expiration: | April 23, 2018
|
| Warrant strike price: | $6.142
|
| Investor: | F2 Bioscience III, LP
|
| Settlement date: | April 23
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
